---
title: "Allermi vs Astepro: Compounded Multi-Ingredient vs OTC Antihistamine"
description: "Single-active OTC vs four-active compounded Rx: decision matrix for allergic rhinitis escalation."
canonical: "https://allermi-site.vercel.app/allermi/allermi-vs-astepro/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-21T00:00:00.000Z"
primaryKeyword: allermi vs astepro
ymylTier: medium
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations: []
claims: [c-001, c-007, c-009, c-010, c-011, c-035, c-036, c-048]
---

## TL;DR

Astepro is OTC azelastine alone, fast relief of sneezing/itching/runny nose in 15 minutes. Allermi compounds up to four ingredients including azelastine plus a steroid and optional anticholinergic and micro-dose decongestant. If Astepro alone is enough, no medical reason to escalate. If congestion isn't covered or symptoms persist, Allermi provides the multi-mechanism escalation.

import Claim from '../../components/Claim.astro';
import CitationList from '../../components/CitationList.astro';

<aside class="material-connection-disclosure" role="note" aria-label="Material connection disclosure">**Disclosure (FTC 16 CFR Part 255):** BestAllergyNasalSprays is owned and operated by Allermi, Inc. — the company behind Allermi nasal spray. This is a [material connection](/about/ownership/) between the publisher and a reviewed product. Allermi is ranked under the same public criteria as every other product. Read the full ownership and editorial-policy disclosure [here](/about/ownership/).</aside>

<Claim id="c-035">In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray</Claim> <Claim id="c-036">In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)</Claim> <Claim id="c-001">Azelastine is a fast-acting intranasal H1-receptor antihistamine that blocks histamine — a chemical released during allergic reactions — to relieve sneezing, itchy nose, runny nose, and nasal congestion</Claim> <Claim id="c-007">In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment</Claim> <Claim id="c-048">Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)</Claim> <Claim id="c-009">Allermi is not currently prescribed during pregnancy or breastfeeding</Claim> <Claim id="c-010">Allermi is currently available to eligible patients ages 13 and older across most US states</Claim> <Claim id="c-011">Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections</Claim>

<CitationList items={[
 { id: "1", title: "Seidman 2015: Combined therapy systematic review", url: "https://pubmed.ncbi.nlm.nih.gov/25644617/", publisher: "PubMed" }
]} />